-
公开(公告)号:US10138291B2
公开(公告)日:2018-11-27
申请号:US14413765
申请日:2013-07-10
Applicant: Bioverativ Therapeutics Inc.
Inventor: Ekta Seth Chhabra , Tongyao Liu , Pei-yun Chang , Robert T. Peters , John Kulman
Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
-
公开(公告)号:US12030925B2
公开(公告)日:2024-07-09
申请号:US16415893
申请日:2019-05-17
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor: Ekta Seth Chhabra , Alison Innes , Dan Rudin , Kara Rice , Nancy Wong , Suresh Katragadda
IPC: A61K38/00 , A61P7/04 , C07K14/755
CPC classification number: C07K14/755 , A61P7/04 , A61K38/00 , C07K2319/30
Abstract: The present disclosure provides a method of treating hemophilia A in a human subject in need thereof comprising administering to the subject a chimeric polypeptide comprising (i) a factor VIII (FVIII) protein and (ii) a von Willebrand factor (VWF) fragment comprising a D′ domain of VWF and a D3 domain of VWF at a dosing interval.
-
公开(公告)号:US11370827B2
公开(公告)日:2022-06-28
申请号:US14371948
申请日:2013-01-12
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor: Ekta Seth Chhabra , Tongyao Liu , Robert T Peters , Haiyan Jiang
IPC: A61K38/37 , C07K14/755 , A61K47/62 , C07K16/00
Abstract: The present invention provides a VWF fragment comprising the D′ domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
-
公开(公告)号:US11192936B2
公开(公告)日:2021-12-07
申请号:US15110673
申请日:2015-01-09
Applicant: Bioverativ Therapeutics Inc.
Inventor: Ekta Seth Chhabra , Tongyao Liu , Robert T. Peters , John Kulman
IPC: C07K14/755 , C07K16/00 , A61K38/00
Abstract: The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D′ domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.
-
公开(公告)号:US11091534B2
公开(公告)日:2021-08-17
申请号:US16154310
申请日:2018-10-08
Applicant: Bioverativ Therapeutics Inc.
Inventor: Ekta Seth Chhabra , Tongyao Liu , Pei-yun Chang , Robert T. Peters , John Kulman , Haiyan Jiang
Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
-
公开(公告)号:US10745680B2
公开(公告)日:2020-08-18
申请号:US15750119
申请日:2016-08-03
Applicant: Bioverativ Therapeutics Inc.
Inventor: Zhiqian Liu , Arjan Van Der Flier , David R. Light , Ekta Seth Chhabra , Tongyao Liu , Robert T. Peters , John Kulman , Ayman Ismail
Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.
-
公开(公告)号:US10548953B2
公开(公告)日:2020-02-04
申请号:US14912047
申请日:2014-08-14
Applicant: Bioverativ Therapeutics Inc.
Inventor: Tongyao Liu , Pei-Yun Chang , John Kulman , Volker Schellenberger , Haiyan Jiang , Robert T. Peters , Ekta Seth Chhabra
Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.
-
-
-
-
-
-